HER2低表达与HER2零表达状态的早期乳腺癌患者的预后差异
Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status.
作者信息
Cha Chihwan David, Kim Kyung Eun, Kim Jungbin, Um Eunhae, Choi Nayeon, Lee Jungsun, Gwak Geumhee, Kim Jae Il, Chung Min Sung
机构信息
Department of Surgery, Hanyang University Medical Center, Hanyang University College of Medicine, Seoul, South Korea.
Division of Breast Surgery, Department of Surgery, Haeundae-Paik Hospital, College of Medicine, Inje University, Busan, South Korea.
出版信息
NPJ Breast Cancer. 2025 Mar 26;11(1):31. doi: 10.1038/s41523-025-00737-8.
We aimed to investigate the differences in prognosis between patients with HER2-low and HER2-zero status. This retrospective cohort study conducted at multi-institution included 1627 patients diagnosed with HER2-low or HER2-zero breast cancer (stages I-III). Survival analysis after propensity score matching was used. In total, 445 patients with HER2-low and 707 patients with HER2-zero status were included. The median follow-up was 92.7 months. Locoregional and distant recurrence-free survival were comparable between patients with HER2-low and HER2-zero status (p = 0.872, p = 0.746, respectively). HER2-low status did not affect overall survival. However, in subgroups with lymph node metastases, patients with HER2-low status showed better recurrence-free survival compared with that of patients with HER2-zero status (p = 0.033). In conclusion, survival outcomes were comparable between patients with HER2-low and HER2-zero breast cancer. More studies are needed to validate our findings and examine the biological mechanism underlying these prognostic differences.
我们旨在研究HER2低表达和HER2零表达状态患者的预后差异。这项在多机构开展的回顾性队列研究纳入了1627例诊断为HER2低表达或HER2零表达乳腺癌（I-III期）的患者。采用倾向评分匹配后的生存分析。总共纳入了445例HER2低表达患者和707例HER2零表达患者。中位随访时间为92.7个月。HER2低表达和HER2零表达状态的患者在局部区域和远处无复发生存方面相当（分别为p = 0.872，p = 0.746）。HER2低表达状态不影响总生存。然而，在有淋巴结转移的亚组中，HER2低表达状态的患者与HER2零表达状态的患者相比，无复发生存更好（p = 0.033）。总之，HER2低表达和HER2零表达乳腺癌患者的生存结果相当。需要更多研究来验证我们的发现并研究这些预后差异背后的生物学机制。
Zotero 插件